C. Chouaid

P. Fournel, F. Guisier, C. Chouaid, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Patients in ICUs Indications of Chest Radiographs for A Web-Based Delphi Study on the

J. Vibert, B. Guidet, C. Chouaid, 2008 .

A web-based Delphi study on the indications of chest radiographs for patients in ICUs.

J. Vibert, A. Valleron, P. Böelle, 2008, Chest.

An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non–Small-Cell Lung Cancer

G. Scagliotti, E. Felip, J. von Pawel, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy and toxicity of mitomycin, ifosfamide, and cisplatin (MIP) in patients with inoperable non-small cell lung cancer.

C. Chouaid, B. Lebeau, T. Urban, 1996, Lung cancer.

Second-line treatments of small-cell lung cancers

G. Quéré, C. Chouaid, A. Vergnenègre, 2017, Expert review of anticancer therapy.

Nivolumab-refractory patients with advanced non-small-cell lung cancer.

J. Trédaniel, M. Wislez, C. Chouaid, 2019, Lung cancer.

Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy.

M. Humbert, S. Eddahibi, G. Simonneau, 2000, American journal of respiratory and critical care medicine.

Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial.

N. Girard, O. Molinier, M. Denis, 2019, Clinical lung cancer.

Chronic bronchitis in the general population: influence of age, gender and socio-economic conditions.

N. Roche, M. Zureik, A. Ferré, 2012, Respiratory medicine.

Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial

G. Chatellier, M. Revel, J. Soria, 2018, European Respiratory Journal.

Frequency of comorbidities in chronic obstructive pulmonary disease, and impact on all-cause mortality: A population-based cohort study.

N. Roche, C. Chouaid, E. van Ganse, 2016, Respiratory medicine.

A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective.

P. Auquier, J. Pujol, F. Barlesi, 2015, Interactive cardiovascular and thoracic surgery.

Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).

F. Barlesi, C. Chouaid, J. Barth, 2018, Lung cancer.

Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab

M. Soussan, N. Girard, L. Mezquita, 2020, Cancers.

What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?--Results from the lung cancer economics and outcomes research (LUCEOR) study.

J. Vansteenkiste, C. Ziske, J. Lester, 2013, Lung cancer.

Association between lung cancer somatic mutations and occupational exposure in never-smokers

P. Dumont, D. Moro-Sibilot, C. Paris, 2017, European Respiratory Journal.

Risk factors for isolation of Streptococcus pneumoniae with decreased susceptibility to penicillin G from patients infected with human immunodeficiency virus.

M. Guiguet, C. Chouaid, J. Meynard, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease.

B. Housset, J. Dubois-Randé, L. Savale, 2009, American journal of respiratory and critical care medicine.

Population characteristics , brachial artery diameter , blood flow , and wall shear stress at baseline and during hyperemia in normocythemic and polycythemic patients

B. Housset, G. Pelle, J. Dubois-Randé, 2011 .

Effects of polycythemia on systemic endothelial function in chronic hypoxic lung disease.

B. Housset, G. Pelle, J. Dubois-Randé, 2011, Journal of applied physiology.

PRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION

P. Cuijpers, J. Reginster, N. Waugh, 2017, International Journal of Technology Assessment in Health Care.

Clinical efficacy and cost-effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration for preoperative staging of non-small–cell lung cancer: Results of a French prospective multicenter trial (EVIEPEB)

C. Marquette, J. Vergnon, L. Thiberville, 2019, PloS one.

Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study.

B. Milleron, F. Barlesi, C. Chouaid, 2010 .

Cost-Effectiveness of Second-Line Chemotherapy for Non-small Cell Lung Cancer: An Economic, Randomized, Prospective, Multicenter Phase III Trial Comparing Docetaxel and Pemetrexed: The GFPC 05-06 Study

C. Chouaid, A. Vergnenègre, R. Corre, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project—Part 2)

J. Pignon, B. Chetaille, J. Solassol, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[Respiratory isolation in suspected tuberculosis with negative direct sputum examination].

C. Chouaid, G. Voiriot, C. Chouaid, 2019, Revue des maladies respiratoires.

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

Keunchil Park, N. Rizvi, J. Mazières, 2018, The Lancet. Oncology.

Lung cancer and interstitial lung disease: a literature review.

M. Antoine, M. Wislez, C. Chouaid, 2018, Journal of thoracic disease.

A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer

G. Zalcman, P. Fournel, C. Chouaid, 2014, BMC Cancer.

Second-line oral chemotherapy (lomustine, cyclophosphamide, etoposide) versus intravenous therapy (cyclophosphamide, doxorubicin, and vincristine) in patients with relapsed small cell lung cancer: a randomized phase II study of GFPC 0501.

C. Chouaid, R. Gervais, N. Baize, 2015, Clinical lung cancer.

A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study).

C. Chouaid, A. Vergnenègre, R. Corre, 2012, Lung cancer.

Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE)

F. Bonnetain, C. Chouaid, J. Bennouna, 2017, Oncology.

Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France

S. Roze, C. Chouaid, K. Le Lay, 2017, ClinicoEconomics and outcomes research : CEOR.

An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer

U. Siebert, S. Walzer, C. Chouaid, 2011, Current medical research and opinion.

Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.

H. Groen, A. Chella, M. Ahn, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer.

U. Siebert, S. Walzer, J. de Castro Carpeno, 2010, Lung cancer.

Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study

J. Soria, J. Mazières, J. Trédaniel, 2015, Clinical Cancer Research.

Treatment of lung cancer: will financial issues become a criterion of choice?

C. Chouaid, A. Vergnenègre, I. Borget, 2013, Expert review of pharmacoeconomics & outcomes research.

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

R. Greil, O. Popovych, C. Gridelli, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses

K. Nackaerts, Siân Jones, A. Chiang, 2020 .

Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for Small-Cell Lung Cancer: Primary and Correlative Biomarker Analyses.

K. Nackaerts, Siân Jones, A. Chiang, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cost‐Effectiveness Analysis of Afatinib versus Gefitinib for First‐Line Treatment of Advanced EGFR‐Mutated Advanced Non–Small Cell Lung Cancers

G. de Pouvourville, D. Moro-Sibilot, C. Chouaid, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Erlotinib Pharmacoeconomic Review of its Use in Advanced Non-Small Cell Lung Cancer

S. Capri, C. Chouaid, E. Orlewska, 2010 .

Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units

N. Girard, J. Timsit, D. Moro-Sibilot, 2014, Intensive Care Medicine.

Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505).

C. Chouaid, A. Vergnenègre, R. Corre, 2013, Clinical lung cancer.

[Chemotherapy at the end of life for patients with lung cancer. A practice analysis].

C. Chouaid, P. Créquit, M. Didier, 2015, Revue des maladies respiratoires.

Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group.

C. Chouaid, C. Audigier-Valette, A. Vergnenègre, 2017, Journal of thoracic disease.

[Management and outcome of French elderly patients with lung cancer: an IFCT survey].

B. Milleron, P. Souquet, P. Girard, 2010, Revue des maladies respiratoires.

Economic Analysis of First‐Line Treatment with Erlotinib in an EGFR‐Mutated Population with Advanced NSCLC

E. Felip, F. de Marinis, R. Rosell, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic review

A. Escande, C. Chouaid, R. Gervais, 2018, Expert review of anticancer therapy.

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019

G. Jeannin, F. Guisier, G. Quéré, 2020, Cancers.

[Management of spinal metastases of lung cancer].

C. Chouaid, S. Gaillard, S. Bennis, 2013, Revue des maladies respiratoires.

Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer

J. Thariat, J. Grellard, J. Faivre, 2019, BMC Cancer.

COPD_A_222762 2905..2915

E. Ganse, C. Chouaid, G. Nachbaur, 2019 .

Current Process and Future Path for Health Economic Assessment of Pharmaceuticals in France.

B. Falissard, A. Millier, M. Toumi, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Current process and future path for health economic assessment of pharmaceuticals in France

B. Falissard, A. Millier, M. Toumi, 2015, Journal of market access & health policy.

Epidemiology and Treatment Costs of Bone Metastases from Lung Cancer

J. Vernejoux, G. Quéré, C. Chouaid, 2011 .

Epidemiology and Treatment Costs of Bone Metastases from Lung Cancer: A French Prospective, Observational, Multicenter Study (GFPC 0601)

J. Vernejoux, G. Quéré, C. Chouaid, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pulmonary Artery Smooth Muscle Cell Senescence Is a Pathogenic Mechanism for Pulmonary Hypertension in Chronic Lung Disease

J. Dubois-Randé, A. Chaouat, M. Alifano, 2011, Circulation research.

Causes of pleural effusion in 75 HIV-infected patients.

M. Denis, C. Chouaid, B. Lebeau, 1993, Chest.

Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies.

B. Housset, J. Tillement, C. Chouaid, 2000, Clinical biochemistry.

Beclin1 circulating levels and accelerated aging markers in COPD

T. Soumagne, E. Audureau, C. Chouaid, 2018, Cell Death & Disease.

Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies.

E. Felip, D. Planchard, L. Paz-Ares, 2016 .

Characteristics of Lung Cancer in Patients Younger than 40 Years: A Prospective Multicenter Analysis in France

J. Mazières, C. Chouaid, H. Colineaux, 2018, Oncology.

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Young Hak Kim, N. Reinmuth, A. Chiang, 2019, The Lancet.

EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients.

M. Antoine, M. Wislez, C. Chouaid, 2016, Lung cancer.

Non-small cell lung cancer, locally advanced

P. Lambin, S. Kozlov, I. Petersen, 2012 .

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study

L. Misery, C. Robert, L. Chiche, 2019, Arthritis & rheumatology.

Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study.

Keunchil Park, N. Rizvi, J. Mazières, 2020, Lung cancer.

Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients

A. Cazes, O. Molinier, J. Trédaniel, 2021, Cancers.

Cost analysis of adverse events associated with non-small cell lung cancer management in France

A. Millier, E. Clay, C. Chouaid, 2017, ClinicoEconomics and outcomes research : CEOR.

Question 5. Stratégies de la réhabilitation respiratoire

G. Ninot, C. Chouaid, J. Lonsdorfer, 2005 .

Simulation-Based Estimates of the Effectiveness and Cost-Effectiveness of Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease in France

G. Hejblum, C. Chouaid, P. Créquit, 2016, PloS one.

Impaired humoral and cellular immune responses to influenza vaccination in chronic obstructive pulmonary disease patients.

B. Housset, Y. Lévy, J. Lelièvre, 2017, The Journal of allergy and clinical immunology.

Comparison of four demand oxygen delivery systems at rest and during exercise for chronic obstructive pulmonary disease.

B. Housset, C. Chouaid, C. Fuhrman, 2004, Respiratory medicine.

Role for interleukin-6 in COPD-related pulmonary hypertension.

B. Housset, S. Eddahibi, L. Savale, 2009, Chest.

Interleukin-6 gene polymorphism confers susceptibility to pulmonary hypertension in chronic obstructive pulmonary disease.

B. Housset, S. Eddahibi, A. Chaouat, 2006, Proceedings of the American Thoracic Society.

Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment.

B. Besse, O. Lambotte, C. Chouaid, 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

J. Vansteenkiste, J. Lester, C. Chouaid, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[The costs of asthma in France and the economic implications of its level of control].

B. Detournay, C. Chouaid, A. Vergnenègre, 2011, Revue des maladies respiratoires.

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.

E. Felip, J. Adam, A. Szczesna, 2016, The Lancet. Oncology.

Cost effectiveness of the induced sputum technique for the diagnosis of Pneumocystis carinii pneumonia (PCP) in HIV-infected patients.

B. Housset, C. Chouaid, B. Lebeau, 1993, The European respiratory journal.

[Management of malignant pericardial effusion in lung cancer].

M. Alifano, C. Chouaid, G. Rousseau-Bussac, 2014, Revue des maladies respiratoires.

Organisation de la réanimation en situation de pandémie de grippe aviaire

B. Régnier, B. Guidet, B. Guery, 2008, Archives de Pédiatrie.

Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study.

P. Souquet, D. Damotte, C. Chouaid, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first-line cisplatin/Pem/Bev in advanced nonsquamous non-small cell lung cancer (nsNSCLC) on overall survival (OS) of patients (pts) on the AVAPERL (MO22089) phase III randomized trial.

H. Groen, A. Chella, M. Ahn, 2013 .

First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation

C. Chouaid, K. Chouahnia, B. Duchemann, 2020, Journal of Cancer Research and Clinical Oncology.

Pulmonary cryptosporidiosis in the acquired immunodeficiency syndrome

C. Chouaid, J. Meynard, D. Binet, 1996, Infection.

[Chronic bronchitis: prevalence and quality of life. Analysis of data from the French Health Interview Survey 2002-2003].

N. Roche, M. Zureik, C. Chouaid, 2009, Revue des maladies respiratoires.

Use of the polymerase chain reaction technique on induced-sputum samples for the diagnosis of Pneumocystis carinii pneumonia in HIV-infected patients. A clinical and cost-analysis study.

B. Housset, C. Chouaid, J. Poirot, 1995, American journal of clinical pathology.

9076 POSTER An Interim Analysis of Health-Related Quality of Life (HRQoL) in Patients With Non-Squamous Non-Small-Cell Lung Cancer (nsNSCLC) Receiving Bevacizumab Vs Bevacizumab+Pemetrexed for Maintenance Therapy in AVAPERL 1

M. Ahn, S. Walzer, F. Barlesi, 2011 .

S. Walzer, C. Chouaid, A. Roughley, 2011 .

Expected Impact of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (Esmo-Mcsb) on Health Technology Assessment

P. Auquier, M. Toumi, C. Chouaid, 2016 .

Polycythemia impairs vasodilator response to acetylcholine in patients with chronic hypoxemic lung disease.

F. Roudot-thoraval, B. Housset, E. Teiger, 1998, American journal of respiratory and critical care medicine.

[Allopurinol hypersensitivity. A possible cause of hepatitis and mucocutaneous eruptions in a patient undergoing antitubercular treatment].

E. Devin, C. Chouaid, C. Housset, 1995, Revue des maladies respiratoires.

Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy

G. Hejblum, C. Chouaid, P. Tilleul, 2009, Current medical research and opinion.

Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02–14

C. Chouaid, P. Dô, P. Thomas, 2019, Advances in Therapy.

Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment

B. Falissard, A. Millier, M. Toumi, 2017, Journal of market access & health policy.

Pulmonary cryptococcosis: localized and disseminated infections in 27 patients with AIDS.

W. Rozenbaum, C. Chouaid, J. Meynard, 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Le coût du cancer du poumon

C. Chouaid, M. Veil-Picard, 2014 .

Interactions between HIV infection and chronic obstructive pulmonary disease: Clinical and epidemiological aspects

N. Roche, C. Chouaid, C. Raynaud, 2011, Respiratory research.

Patient preference for chronic obstructive pulmonary disease (COPD) treatment inhalers: a discrete choice experiment in France

G. de Pouvourville, P. Devillier, M. Toumi, 2019, Current medical research and opinion.

Usefulness of PCR for detection of Pneumocystis carinii DNA

M. Miltgen, M. Denis, J. Olivier, 1994, Journal of clinical microbiology.

Value of an immunofluorescence assay for the detection of Pneumocystis carinii in Bronchoalveolar lavage.

M. Denis, C. Chouaid, J. Poirot, 1991, The Journal of protozoology.

PCR for Detection of Pneumocystis carinii in Blood Cells

M. Miltgen, M. Denis, J. Olivier, 1995 .

Pulmonary toxoplasmosis in HIV-infected patients: usefulness of polymerase chain reaction and cell culture.

J. Olivier, C. Chouaid, J. Poirot, 1995, The European respiratory journal.

Infections non tuberculeuses

C. Chouaid, 2003 .

An open multicenter phase II trial of docetaxel-gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell lung cancer (NSCLC): the GFPC 02-02a study.

P. Fournel, C. Chouaid, A. Vergnenègre, 2007, Critical reviews in oncology/hematology.

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.

S. Peters, E. Felip, J. Mazières, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer

F. Guisier, C. Chouaid, R. Gervais, 2017, Targeted Oncology.

Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis.

N. Roche, A. Dechartres, P. Forgez, 2013, The Journal of thoracic and cardiovascular surgery.

1263PAFATINIB (A) FOLLOWED BY A + PACLITAXEL (P) OR INVESTIGATOR'S CHOICE OF SINGLE-AGENT CHEMOTHERAPY (IC) IN PATIENTS (PTS) WITH ADVANCED SQUAMOUS CELL CARCINOMA (SCC) OF THE LUNG: SUBGROUP ANALYSIS OF LUX-LUNG 5 (LL5).

J. Strausz, F. de Marinis, D. Planchard, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

1265PPATIENT-REPORTED OUTCOMES (PROS) IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) RECEIVING AFATINIB (A) MONOTHERAPY FOLLOWED BY A + PACLITAXEL (A + P) VS INVESTIGATOR'S CHOICE OF SINGLE-AGENT CHEMOTHERAPY (IC): LUX-LUNG 5 (LL5).

F. de Marinis, D. Planchard, M. Schuler, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01).

C. Chouaid, A. Vergnenègre, H. Léna, 2014, Lung cancer.

Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.

B. Milleron, M. Taron, G. Zalcman, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeted therapies in non-small-cell lung cancer management: no cost-effective strategies?

C. Chouaid, A. Vergnenègre, I. Borget, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Modeling the critical care demand and antibiotics resources needed during the Fall 2009 wave of influenza A(H1N1) pandemic

Daniela Paolotti, Alessandro Vespignani, Nicola Perra, 2009, PLoS currents.

[Choriocarcinoma with pulmonary metastasis: diagnosis and treatment].

C. Chouaid, I. Papanikolaou, L. Bengrine-Lefevre, 2009, Revue des maladies respiratoires.

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

J. Lafitte, L. Freitag, J. von Pawel, 2008, British Journal of Cancer.

Salvage Immunotherapy With Pembrolizumab in Patients Hospitalized for Life-Threatening Complications of NSCLC

C. Gauvain, C. Chouaid, V. Leroy, 2021, JTO clinical and research reports.

Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02–14 Study)

C. Chouaid, A. Vergnenègre, C. Dubos-Arvis, 2017, Targeted Oncology.

[Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement].

K. Leroy, A. Boudjemaa, C. Chouaid, 2017, Revue des maladies respiratoires.

Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.

C. Chouaid, R. Gervais, P. Saulnier, 2020, The Lancet. Oncology.

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer

F. Lucia, G. Quéré, R. Descourt, 2020, Cancer medicine.

Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma

P. Fournel, F. Guisier, C. Chouaid, 2020, Medicine.

Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).

D. Planchard, F. Guisier, M. Wislez, 2019, Lung cancer.

Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study

P. Fournel, C. Chouaid, R. Gervais, 2016, Targeted Oncology.

Phase 2 Study of the HSP‐90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer

H. Groen, L. Sequist, E. Smit, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study)

F. Guisier, R. Descourt, C. Chouaid, 2018, Oncotarget.

Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3

J. Pignon, C. Chouaid, E. Quoix, 2011, European Respiratory Journal.

Comparative cost-effectiveness of three strategies for guiding second-line erlotinib initiation in non small-cell lung cancer: a French prospective multicenter study (ERMETIC Project Part 3) Short title: Erlotinib cost-effectiveness analysis in second-line lung cancer therapy

Isabelle, C. Chouaid, É. Dansin, 2011 .

Empyema of the thorax due to Gemella haemolysans.

B. Housset, N. Veziris, C. Chouaid, 1999, The Journal of infection.

Attitudes to prevention among HIV-infected patients: the case of specific prophylaxis for Pneumocystis carinii pneumonia.

A. Aupérin, C. Chouaid, V. D. des Fontaines, 1994, Health policy.

A. Chella, M. Ahn, Joo‐Hang Kim, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis

P. Fournel, C. Chouaid, A. Vergnenègre, 2007, Current medical research and opinion.

Patients with non-small-cell lung cancer harbouring a BRAF mutation: a multicentre study exploring clinical characteristics, management, and outcomes in a real-life setting: EXPLORE GFPC 02-14.

C. Chouaid, R. Gervais, A. Vergnenègre, 2018, Current oncology.

Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.

A. Millier, E. Clay, C. Chouaid, 2019, Lung cancer.

A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer.

Tuan S. Nguyen, W. Engel-Riedel, J. Mazières, 2015, Lung cancer.

Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study).

O. Molinier, J. Mazières, G. Zalcman, 2015, Lung cancer.

Management and treatment outcomes of tuberculous patients, eastern Paris, France, 2004.

G. Hejblum, C. Chouaid, H. Mallet, 2009, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model.

B. Housset, C. Chouaid, C. Fuhrman, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study.

W. Curran, M. Krzakowski, C. Chouaid, 2010, Clinical lung cancer.

Induction (ICT) or consolidation chemotherapy (CT) with cisplatin (C) and paclitaxel (P) plus concurrent chemo-radiation (CT/TRT) with cisplatin and vinorelbine (V) for unresectable non-small cell lung cancer (NSCLC) patients (pts): Randomized phase II trial GFPC-GLOT-IFCT 02-01.

P. Souquet, P. Fournel, C. Chouaid, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anti PD-(L)1 in KRAS mutant advanced nsclcs: A meta-analysis of randomized controlled trials.

C. Chouaid, K. Chouahnia, B. Duchemann, 2021 .

[Clinical burden caused by hospitalization for febrile neutropenia in France in 2010-2011: An analysis of the PMSI database].

F. Scotté, C. Chouaid, G. Freyer, 2016, Bulletin du Cancer.

Factors associated with excessively lengthy treatment of tuberculosis in the eastern Paris region of France in 2004

G. Hejblum, C. Chouaid, H. Mallet, 2010, BMC public health.

Beclin1 circulating levels and accelerated aging markers in COPD

T. Soumagne, E. Audureau, C. Chouaid, 2018, Cell Death & Disease.

[Adult asthma exacerbations in questions].

M. Humbert, I. Tillie‐Leblond, L. Bertoletti, 2010, Revue des maladies respiratoires.

A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study)

F. Barlesi, C. Chouaid, A. Vergnenègre, 2011, British Journal of Cancer.

An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study.

F. Barlesi, P. Fournel, C. Chouaid, 2007, Lung cancer.

Multidimensional analyses to assess the relations between treatment choices by physicians and patients’ characteristics: the example of COPD

N. Roche, B. Delclaux, C. Chouaid, 2012, BMC Pulmonary Medicine.

' s response to reviews Title : Multidimensional analysis to assess the relations between treatment choices by physicians and patients ' characteristics : the example of COPD

N. Roche, B. Delclaux, C. Chouaid, 2012 .

The Burden of Severe Asthma in France: A Case-Control Study Using a Medical Claims Database.

J. Gourmelen, C. Chouaid, A. Bourdin, 2019, The journal of allergy and clinical immunology. In practice.

Are Systemic Manifestations Ascribable to COPD in Smokers? A Structural Equation Modeling Approach

B. Housset, E. Audureau, G. Derumeaux, 2014, Scientific Reports.

Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study

F. Barlesi, P. Souquet, P. Fournel, 2007, Targeted Oncology.

Simulation-Based Estimates of Effectiveness and Cost-Effectiveness of Smoking Cessation in Patients with Chronic Obstructive Pulmonary Disease

G. Hejblum, C. Chouaid, K. Atsou, 2011, PloS one.

Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review

G. Hejblum, C. Chouaid, K. Atsou, 2011, BMC medicine.

Delays for diagnosis and treatment of lung cancers: a systematic review

C. Chouaid, I. Monnet, I. Ben Hassen, 2016, The clinical respiratory journal.

Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis

J. Pairon, A. Scherpereel, C. Chouaid, 2018, Cancer medicine.

Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.

D. Planchard, F. Guisier, M. Wislez, 2019, Lung cancer.

Isolated 5′ Signals Are an Atypical Pattern To Be Considered as Positive for ALK Rearrangement: A Brief Report of Three Cases and Review of the Literature1

C. Copie-Bergman, K. Leroy, C. Chouaid, 2019, Translational oncology.

Routine once-weekly darbepoetin alfa administration is cost-effective in lung cancer patients with chemotherapy-induced anemia: a Markov analysis.

C. Chouaid, P. Tilleul, I. Borget, 2005, Lung cancer.

Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer

P. Fournel, G. Quéré, C. Chouaid, 2019, Targeted Oncology.

Cost-benefit analysis of a simulated institution-based preoperative smoking cessation intervention in patients undergoing total hip and knee arthroplasties in France.

B. Dautzenberg, G. Hejblum, C. Chouaid, 2009, Chest.

Lung cancer survivors and employment: A systematic review.

C. Chouaid, F. Savall, J. Soulat, 2019, Lung cancer.

Evaluation of the Idylla system to detect the EGFRT790M mutation using extracted DNA.

J. Tran van Nhieu, Loëtitia Favre, C. Chouaid, 2019, Pathology, research and practice.

Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01.

J. Daurès, P. Souquet, P. Fournel, 2016, European journal of cancer.

Preclinical and Preliminary Clinical Activity of NVP-BKM120, an Oral Pan-Class I PI3K Inhibitor, in the Brain

C. Schnell, P. Lollini, P. Schmid, 2012 .

The association between asthma control, health care costs, and quality of life in France and Spain

B. Detournay, C. Chouaid, L. Com-ruelle, 2013, BMC Pulmonary Medicine.

Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study.

F. Barlesi, C. Chouaid, J. Barth, 2018, Lung cancer.

Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy.

N. Girard, L. Mezquita, C. Chouaid, 2021, Lung cancer.

A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France

C. Chouaid, J. Eaton, G. Sleilaty, 2017, ClinicoEconomics and outcomes research : CEOR.

CPAP titration by an auto-CPAP device based on snoring detection: a clinical trial and economic considerations.

F Lofaso, C Chouaid, A. Harf, 1998, The European respiratory journal.

French Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends

M. Toumi, C. Chouaid, I. Borget, 2016, Targeted Oncology.

Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain.

F. de Marinis, S. Walzer, J. de Castro Carpeno, 2011, Lung cancer.

Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients

L. Thiberville, J. Mazières, D. Moro-Sibilot, 2018, ERJ Open Research.

Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study.

A. Labrunie, P. Fournel, R. Descourt, 2014, Lung cancer.

Medical follow-up of workers exposed to lung carcinogens: French evidence-based and pragmatic recommendations

P. Grenier, F. Laurent, B. Milleron, 2017, BMC Public Health.

Perception of alopecia by patients requiring chemotherapy for non-small-cell lung cancer: a willingness to pay study.

C. Chouaid, P. Tilleul, M. Bernard, 2011, Lung cancer.

MA07.06 Immunotherapy Re-Challenge After Nivolumab Treatment in Advanced Non-Small Cell Lung Cancer in French Real-World Setting

C. Chouaid, F. Cotté, A. Gaudin, 2019, Journal of Thoracic Oncology.

FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer

M. Soussan, N. Girard, C. Chouaid, 2020, Annals of Nuclear Medicine.

Cost effectiveness of noninvasive oxygen saturation measurement during exercise for the diagnosis of Pneumocystis carinii pneumonia.

B. Housset, C. Chouaid, B. Lebeau, 1993, The American review of respiratory disease.

Efficacy of Pemetrexed as Second-Line Therapy in Advanced NSCLC after Either Treatment-Free Interval or Maintenance Therapy with Gemcitabine or Erlotinib in IFCT-GFPC 05-02 Phase III Study

F. Barlesi, P. Fournel, C. Chouaid, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Economics of Treatments for Non-Small Cell Lung Cancer

G. Hejblum, C. Chouaid, A. Vergnenègre, 2012, PharmacoEconomics.

[Comprehensive geriatric assessment and complications after resection for lung cancer].

C. Chouaid, I. Borget, C. Raynaud, 2010, Revue des maladies respiratoires.

Monitoring Subsolid Pulmonary Nodules in High-Risk Patients Is Even More Cost-Effective When Combined With a Stop-Smoking Program.

C. Chouaid, S. Gendarme, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study

R. Abgral, U. Schick, G. Quéré, 2020, Cancer medicine.

Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer

J. Trédaniel, M. Wislez, C. Chouaid, 2018, ERJ Open Research.

Anti PD-1 (nivolumab, pembrolizumab) or anti PD-L1 (atezolizumab) versus docetaxel for previously treated patients with advanced NSCLC: A meta-analysis.

C. Chouaid, A. Vergnenègre, P. Nicolas, 2016 .

Pulmonary ttoxoplasmosis iin H HIV-infected p patients: u usefulness o of polymerase c chain rreaction a and c cell c culture

C. Chouaid, P. Roux, I. Lavrard, 1995 .

G. Zalcman, P. Fournel, C. Chouaid, 2014, BMC Cancer.

Cutaneous lymphangitis carcinomatosa in a patient with lung adenocarcinoma: case report and literature review.

C. Chouaid, A. Kettaneh, L. Fardet, 2013, Lung cancer.

[A prospective study of quality of life and treatment of chemotherapy-induced anaemia in lung cancer].

C. Chouaid, P. Tilleul, I. Borget, 2007, Revue des maladies respiratoires.

Impact of Therapy Persistence on Exacerbations and Resource Use in Patients Who Initiated COPD Therapy

C. Chouaid, G. Nachbaur, E. van Ganse, 2019, International journal of chronic obstructive pulmonary disease.

Lung cancer and end-of-life care: a systematic review and thematic synthesis of aggressive inpatient care

C. Chouaid, O. Bylicki, J. Margery, 2019, BMJ Supportive & Palliative Care.

Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study.

N. Girard, C. Maritaz, D. Moro-Sibilot, 2020, Future oncology.

Economic impact of second- and third-line erlotinib treatment of non small-cell lung cancer: a French observational study: P1-245

C. Chouaid, A. Vergnenègre, C. Coudray-Omnès, 2007, Revue des maladies respiratoires.

Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy

F. de Marinis, D. Gultyaev, S. Walzer, 2015, Expert review of anticancer therapy.

Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC).

E. Mueller, S. Walzer, C. Chouaid, 2010, Lung cancer.

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer

S. Walzer, J. Ray, C. Chouaid, 2012, ClinicoEconomics and outcomes research : CEOR.

[Thiamine deficiency. A cause of cardiac insufficiency not to be ignored].

B. Housset, C. Chouaid, C. Fuhrman, 1998, Revue des maladies respiratoires.

Cost-analysis of four diagnostic strategies for Pneumocystis carinii pneumonia in HIV-infected subjects.

B. Housset, C. Chouaid, B. Lebeau, 1995, European Respiratory Journal.

Continuity of care in general practice at cancer diagnosis (COOC-GP study): a national cohort study of 2853 patients.

M. Aubin, E. Audureau, C. Chouaid, 2019, The British journal of general practice : the journal of the Royal College of General Practitioners.

Are Systemic Manifestations Ascribable to COPD in Smokers? A Structural Equation Modeling Approach

B. Housset, E. Audureau, G. Derumeaux, 2018, Scientific Reports.

[Impact of a multidisciplinary approach for monitoring prescribing of antibiotics in a hospital].

A. Thébault, C. Chouaid, R. Cohen, 1998, Presse medicale.

Failure Mode, Effects and Criticality Analysis (FMECA) as a means of improving the hospital drug prescribing process

Christos Chouaid, S. Saizy-Callaert, R. Causse, 2002 .

Real-Life-Setting Effectiveness of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: The Remix Study

N. Texier, M. Macro, X. Leleu, 2020 .

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

F. Cappuzzo, D. Gandara, D. Planchard, 2015, The Lancet. Oncology.

Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents

C. Chouaid, A. Vergnenègre, I. Borget, 2013, ClinicoEconomics and outcomes research : CEOR.

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe

S. Walzer, M. Tiseo, J. Ray, 2012, ClinicoEconomics and outcomes research : CEOR.

A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.

S. Walzer, C. Chouaid, D. Heigener, 2012, Lung cancer.